By |

Equities News

Company chart and information is provided by TradingView based on 15-minute-delayed data.


Profile

Galapagos NV is a clinical-stage biotechnology company, involved in the discovery and development of small-molecule medicines. The company's product candidate portfolio includes Filgotinib, a JAK1 inhibitor to treat rheumatoid arthritis, Crohn's disease, and ulcerative colitis; novel therapies in cystic fibrosis (a chronic disease that affects the lungs and digestive system); GLPG1690, a selective autotaxin inhibitor with potential application in idiopathic pulmonary disease; GLPG1972 to treat osteoarthritis; and MOR106 to treat atopic dermatitis.

Contact Information

Website: www.glpg.com
Email: ir@glpg.com
Main Phone: +32 15342900
Address: Generaal De Wittelaan L11 A3
Address 2: Suite 4000
State: AB
City / Town: Mechelen
Country: BE
Postal Code: 2800

Issuer Information

Exchange: NGS
CEO: Onno van de Stolpe
Employees: 1304
NAICS: Pipeline Transportation of Crude Oil(486110)

Equities News

(%)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size N/A Ask N/A Ask Size N/A
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume N/A 52 Wk Hi N/A 52 Wk Low N/A
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares N/A EPS (TTM) N/A PE Ratio N/A Exchange N/A